The United States Patent and Trademark Office (USPTO) has officially registered trademark application TM86527529 for the mark "IMPRIMIS," specifically for pharmaceutical compounding services. This registration, filed on February 6, 2015, was finalized on March 28, 2026, granting exclusive rights for the use of this mark in connection with the specified services.

This registration signifies a completed intellectual property action by the USPTO. For entities involved in pharmaceutical compounding, this means the mark "IMPRIMIS" is now protected for its owner, and other businesses should avoid using similar marks for related services to prevent potential infringement claims. No immediate compliance actions are required for other parties, but legal counsel should be consulted if there are concerns about mark usage or potential conflicts.